| Identification | Back Directory | [Name]
N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide | [CAS]
1428327-31-4 | [Synonyms]
JNJ-479655
JNJ-47965567
JNJ-47965567 >=98% (HPLC)
JNJ-47965567
(JNJ47965567)
N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE
N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide
2-(Phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl-3-pyridinecarboxamide
3-Pyridinecarboxamide, 2-(phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl]- | [Molecular Formula]
C28H32N4O2S | [MDL Number]
MFCD28334214 | [MOL File]
1428327-31-4.mol | [Molecular Weight]
488.64 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMF:30.0(Max Conc. mg/mL);61.39(Max Conc. mM)
DMSO:59.62(Max Conc. mg/mL);122.01(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.51(Max Conc. mM)
Ethanol:12.5(Max Conc. mg/mL);25.58(Max Conc. mM) | [form ]
powder | [color ]
white to beige |
| Hazard Information | Back Directory | [Description]
JNJ-47965567 is a selective antagonist of the purinergic receptor P2X subtype 7 (P2X7), a ligand-gated ion channel. Activation of P2X receptors by BzATP induces calcium flux, which is reduced by JNJ-47965567 in 1321N1 cells transfected with recombinant P2X7 human, macaque, dog, rat, or mouse protein with pIC50s of 8.3, 8.6, 8.5, 7.2, or 7.5, respectively. JNJ-47965567 suppresses neonatal hypoxia-induced seizures in mice and has some anticonvulsant properties in rats. It also reduces spontaneous seizures in epileptic mice even after treatment is stopped. | [Uses]
2-(Phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl]-3-pyridinecarboxamide is a potent and selective human P2X7 antagonist. | [Biochem/physiol Actions]
JNJ-47965567 is a potent P2X7 antagonist with high affinity for the rat receptor (pKi = 8.7). It is centrally available after systemic injection with a superior brain:plasma distribution compared to other available P2X7 antagonists. JNJ-47965567 was shown to suppress epileptic seizures in a mouse model of epilepsy. It appears to have a disease modifying effect since spontaneous seizure rates did not increase once treatment with JNJ-477965567 was stopped. | [in vivo]
JNJ-47965567 (30-100 mg/kg; s.c.) attenuates IL-1β release induced by Bz-ATP[1].
JNJ-47965567 (30 mg/kg) attenuates amphetamine-induced hyperactivity and exhibits modest, yet significant efficacy in the rat model of neuropathic pain[1].
| Animal Model: | Male Sprague Dawley rats[1] | | Dosage: | 30 mg/kg, 100 mg/kg | | Administration: | Subcutaneous injection; 30 minutes prior to Bz-ATP infusion | | Result: | Significantly attenuated IL-1β release at 100 mg/kg, with no effect at 30 mg/kg dose group. |
| [IC 50]
P2X7 Receptor | [storage]
Store at +4°C | [References]
[1] ANINDYA BHATTACHARYA. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567[J]. British Journal of Pharmacology, 2013, 170 3: 624-640. DOI: 10.1111/bph.12314
[2] NATALIA RODRIGUEZ-ALVAREZ . Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice[J]. Neuropharmacology, 2017, 116: Pages 351-363. DOI: 10.1016/j.neuropharm.2017.01.005
[3] WOLFGANG FISCHER. Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models.[J]. PLoS ONE, 2016: e0156468. DOI: 10.1371/journal.pone.0156468
[4] ALBA JIMENEZ-PACHECO. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.[J]. Journal of Neuroscience, 2016, 36 22: 5920-5932. DOI: 10.1523/jneurosci.4009-15.2016 |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|